Current Therapeutic Approaches and Promising Perspectives of Using Bioengineered Peptides in Fighting Chemoresistance in Triple-negative Breast Cancer
Triple Negative Breast Neoplasms, Chemotherapy, Drug Resistance, Peptides, Peptide Library, Pharmaceutical Preparations
Digital Object Identifier (DOI)
Breast cancer is a collation of malignancies that manifest in the mammary glands at the early stages. Among breast cancer subtypes, triple-negative breast cancer (TNBC) shows the most aggressive behavior, with apparent stemness features. Owing to the lack of response to hormone therapy and specific targeted therapies, chemotherapy remains the first line of the TNBC treatment. However, the acquisition of resistance to chemotherapeutic agents increase therapy failure, and promotes cancer recurrence and distant metastasis. Invasive primary tumors are the birthplace of cancer burden, though metastasis is a key attribute of TNBC-associated morbidity and mortality. Targeting the chemoresistant metastases-initiating cells via specific therapeutic agents with affinity to the upregulated molecular targets is a promising step in the TNBC clinical management. Exploring the capacity of peptides as biocompatible entities with the specificity of action, low immunogenicity, and robust efficacy provides a principle for designing peptide-based drugs capable of increasing the efficacy of current chemotherapy agents for selective targeting of the drug-tolerant TNBC cells. Here, we first focus on the resistance mechanisms that TNBC cells acquire to evade the effect of chemotherapeutic agents. Next, the novel therapeutic approaches employing tumor-targeting peptides to exploit the mechanisms of drug resistance in chemorefractory TNBC are described.
Was this content written or created while at USF?
Citation / Publisher Attribution
Biochemical Pharmacology, v. 210, art. 115459
Scholar Commons Citation
Azari, Mandana; Bahreini, Farbod; Uversky, Vladimir N.; and Rezaei, Nima, "Current Therapeutic Approaches and Promising Perspectives of Using Bioengineered Peptides in Fighting Chemoresistance in Triple-negative Breast Cancer" (2023). Molecular Medicine Faculty Publications. 1056.